ETOPOSIDE TREATMENT IN RECURRENT MEDULLOBLASTOMA

被引：10

作者：

BOOR, R

HUBER, A

GUTJAHR, P

机构：

[1] Universitatskinderklink, D-55101 Mainz

来源：

NEUROPEDIATRICS | 1994年 / 25卷 / 01期

关键词：

ETOPOSIDE; RECURRENT MEDULLOBLASTOMA;

D O I：

10.1055/s-2008-1071580

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m(2) for 5 to 7 days at 2 to 4-week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosin arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60 + months. Etoposide seems to be an active agent in medulloblastoma.

引用

页码：39 / 41

页数：3

共 25 条

[1] CARBOPLATIN AND RECURRENT CHILDHOOD BRAIN-TUMORS [J].

ALLEN, JC ;

WALKER, R ;

LUKS, E ;

JENNINGS, M ;

BARFOOT, S ;

TAN, C .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :459-463

[2]

BACHA DM, 1986, CANCER TREAT REP, V70, P865

[3]

CASTELLO MA, 1990, AM J PEDIAT HEMATOL, V12, P297

[4] THE CLINICAL-PHARMACOLOGY OF ETOPOSIDE AND TENIPOSIDE [J].

CLARK, PI ;

SLEVIN, ML .

CLINICAL PHARMACOKINETICS, 1987, 12 (04) :223-252

[5]

COHEN ME, 1984, BRAIN TUMORS CHILDRE, P103

[6]

CREAVEN PJ, 1975, CLIN PHARMACOL THER, V18, P221

[7]

CREAVEN PJ, 1982, CANCER CHEMOTH PHARM, V7, P133

[8] DO ANTICANCER AGENTS REACH THE TUMOR TARGET IN THE HUMAN BRAIN [J].

DONELLI, MG ;

ZUCCHETTI, M ;

DINCALCI, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (04) :251-260

[9]

FINN GP, 1985, CANCER TREAT REP, V69, P603

[10]

GIANNONE L, 1987, CANCER TREAT REP, V71, P759

← 1 2 3 →